Consultant Haematologist Dr Adam Facey joins Ballarat Cancer Care
February 2, 2026

Consultant Haematologist Dr Adam Facey joins Ballarat Cancer Care

Adam completed his medical and medical science Honours degrees at Monash University in 2014. He completed basic physician training at Alfred Health with advanced clinical and laboratory training at Alfred Health, Monash Health, Melbourne Pathology and University Hospital Geelong. He maintains good working relationships with haematologists at these metropolitan health services, expanding access to clinical trials and other specialist treatments not available in the region.

 

Having grown up in Ballarat, Adam is passionate about equitable access to good quality specialist healthcare. He also works at Grampians Health (Ballarat and Horsham), Dorevitch Pathology, and teaches medical students at Deakin University’s Ballarat Clinical School.

 

He loves the diversity that haematology specialisation brings, competent in the diagnosis and management of both malignant (leukaemia, lymphoma and myeloma) and non-malignant (bleeding and thrombosis) diseases. Adam prides himself on clear patient communication, education and shared patient decision-making, particularly in complex cases.

Dr Adam Facey - Ballarat Cancer Care
Haematologist Dr Marsali Maclean joins Ballarat Cancer Care
February 16, 2025
Haematologist Dr Marsali Maclean joins Ballarat Cancer Care
December 3, 2024
We are pleased to announce palliative care physician Dr Russell Pearce will be joining our team in February 2025.
New haematologist  joining the Ballarat Cancer Care team
August 27, 2024
We are excited to announce Dr Tishya Indran will be joining our team as of 18th September 2024. 
4th Dose COVID-19 Vaccine for Immunocompromised Patients
March 1, 2022
The Australian Technical Advisory Group on Immunisation (ATAGI) has approved a fourth dose of a COVID-19 vaccine for people with weakened immune systems. People aged 18 years or older with weakened immune system who received a 3-dose primary course of the COVID-19 vaccine are now recommended to receive the fourth dose ≥ 3 months after their third dose. This is expected to improve protection against symptomatic infection, serious illness, or death from COVID-19 infection.
COVID-19 Vaccine Booster Shots In Our Patients With Cancer
November 8, 2021
The Government and the Medical advisory group (ATAGI) have release new recommendations last week for individuals who are severely immunocompromised in regards to the COVID-19 vaccine. These recommendations will affect some (but not all) of our patients. As always, we are happy to discuss any of the recommendations further with all of our patients.
COVID-19 Vaccination FAQs July 2021
July 20, 2021
In the last few months, I have been inundated with many questions regarding COVID-19 vaccination and blood clots from patients and other health practitioners. In this article, I have compiled these frequently asked questions.
New PBS listings!
July 2, 2021
Despite a global pandemic, new data relating to oncology treatments continues to be published, and it seems that this is increasingly translating into improved drug access here in Australia.
Astra Zeneca (AZ) vaccine safety information
March 26, 2021
In light of recent reports of clotting events following Astra Zeneca (AZ) vaccine in Europe - we have been frequently asked questions regarding the safety of AZ vaccine in patients with previous clot events and/or blood problems
February 25, 2021
Two vaccines against the coronavirus have now been approved for use in Australia, role-out of the vaccine begins this week in high-risk populations.
January 18, 2021
Dr Swe Myo Htet Consultant Haematologist MBBS, FRACP, FRCPA, MRCP